Morphosys said it would concentrate its research activities on its most advanced programs for its four top drugs. The four begin with Monjuvi® (tafasitamab-cxix), marketed as a therapy for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide; and Pelabresib (CPI-0610), being studied as a first-line treatment for myelofibrosis. MorphoSys has also committed to advancing CPI-0209, developed to treat advanced solid tumors and hematologic malignancies; and felzartamab, developed to treat Immunoglobulin A nephropathy and anti-PLA2R-positive membranous nephropathy . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Two by 2025: MorphoSys Consolidates R&D, Retains Commercialization Goal appeared first on GEN – Genetic Engineering and Biotechnology News.
